Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX 75390.
Department of Neuroscience, University of Texas Southwestern Medical Center, Dallas, TX 75390.
J Neurosci. 2022 Mar 30;42(13):2804-2823. doi: 10.1523/JNEUROSCI.1230-21.2021. Epub 2022 Feb 21.
The cerebellum has been increasingly implicated in autism spectrum disorder (ASD) with many ASD-linked genes impacting both cerebellar function and development. However, the precise timing and critical periods of when abnormal cerebellar neurodevelopment contributes to ASD-relevant behaviors remains poorly understood. In this study, we identify a critical period for the development of ASD-relevant behaviors in a cerebellar male mouse model of tuberous sclerosis complex (TSC), by using the mechanistic target of rapamycin (mTOR) inhibitor, rapamycin, to pharmacologically inhibit dysregulated downstream signaling. We find independent critical periods during which abnormal ASD-relevant behaviors develop for the two core ASD diagnostic criteria, social impairments and behavioral flexibility, and delineate an anatomic, physiological, and behavioral framework. These findings not only further our understanding of the genetic mechanisms underlying the timing of ASD-relevant behaviors but also have the capacity to inform potential therapies to optimize treatment interventions. No targeted treatments currently exist for autism spectrum disorder (ASD). This complex developmental disorder has established links to genetic and circuit aberrations, yet the precise timing and coordination of these underlying mechanisms that contribute to the spectrum of physiological and behavioral abnormalities remains unclear. Cerebellar pathology is consistently seen in ASD individuals; therefore, we sought to identify the specific windows for cerebellar involvement in the development of ASD-relevant behaviors. Using pharmacologic treatment paradigms, we outline distinct critical periods of developmental vulnerability for ASD-relevant social and inflexible behaviors. From this study, we posit a refined window of time during which ASD symptoms develop that will inform therapeutic timing.
小脑越来越多地与自闭症谱系障碍(ASD)有关,许多与 ASD 相关的基因会影响小脑的功能和发育。然而,小脑神经发育异常导致与 ASD 相关行为的确切时间和关键期仍然知之甚少。在这项研究中,我们通过使用雷帕霉素(mTOR 抑制剂)来抑制失调的下游信号,在结节性硬化症(TSC)的雄性小脑小鼠模型中确定了与 ASD 相关行为发展的关键期。我们发现,两个核心 ASD 诊断标准(社交障碍和行为灵活性)的异常 ASD 相关行为的发展存在独立的关键期,并描绘了一个解剖学、生理学和行为框架。这些发现不仅进一步了解了 ASD 相关行为时间背后的遗传机制,而且还有潜力为优化治疗干预的潜在治疗方法提供信息。目前尚无针对自闭症谱系障碍(ASD)的靶向治疗方法。这种复杂的发育障碍与遗传和电路异常有关,但导致生理和行为异常谱系的这些潜在机制的确切时间和协调仍然不清楚。小脑病理学在 ASD 个体中经常出现;因此,我们试图确定小脑参与 ASD 相关行为发展的具体窗口期。通过药理治疗方案,我们概述了与 ASD 相关的社交和不灵活行为发展的不同关键脆弱期。从这项研究中,我们提出了一个更精确的 ASD 症状发展时间窗口,这将为治疗时机提供信息。